Neuron23

Neuron23 collaborates with leading geneticists and valuable partners like Origenis, leveraging genetic breakthroughs and artificial intelligence technologies to discover promising approaches and develop new drugs more efficiently than ever before.Neuron23's pipeline focuses on providing appropriate treatments for patients with genetic diseases across disciplines ranging from neurodegenerative to immunological disorders. Currently, Neuron23 has a substantial number of preclinical small-molecule drug candidates, has engaged in drug discovery collaborations with Origenis, and obtained licensing. Our lead candidate targets LRRK2 as a potential treatment for Parkinson’s disease.